• Passage Bio disclosed a $70 million private placement tied to its planned merger with Remix Therapeutics.
• Accredited investors will buy Remix common stock or pre-funded warrants at USD 1.39 per share or USD 1.39 per warrant.
• The financing is set to close immediately before the first step of the merger, subject to deal conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-035515), on September 03, 2026, and is solely responsible for the information contained therein.